FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2335863544> ?p ?o ?g. }

• W2335863544 endingPage "19812" @default.
• W2335863544 startingPage "19794" @default.
• W2335863544 abstract "// Senlin Zhao 1, * , Huamei Tang 2, * , Dongwang Yan 1, * , Junwei Fan 1, * , Hongcheng Sun 1 , Yugang Wen 1 , Fudong Yu 1 , Feifei Cui 1 , Dongyuan Zhang 1 , Yingming Xue 1 , Chenchen Liu 1 , Ben Yue 1 , Jian Chen 1 , Jingtao Wang 1 , Xiao Wang 1 , Meng Zhang 3 , Yang Yu 1 , Weiliang Jiang 4 , Xisheng Liu 1 , Yushuai Mi 1 , Zongguang Zhou 5 , Xuebin Qin 6 , Zhihai Peng 1 1 Department of General Surgery, Shanghai First People’s Hospital, Affiliated to Shanghai Jiao Tong University, Shanghai, China 2 Department of Pathology, Shanghai First People’s Hospital, Affiliated to Shanghai Jiao Tong University, Shanghai, China 3 Department of Pathology, Fudan University Affiliated Shanghai Cancer Center, Shanghai, China 4 Department of Gastroenterology, Shanghai First People’s Hospital, Affiliated to Shanghai Jiaotong University, Shanghai, China 5 Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China 6 Department of Neuroscience, Temple University School of Medicine, Philadelphia, PA, USA * These authors contributed equally to this work Correspondence to: Zhihai Peng, e-mail: pengpzhh@hotmail.com Xuebin Qin, e-mail: xuebin.qin@temple.edu Zongguang Zhou, e-mail: zhouzzghuaxi@163.com Keywords: DDA1, colon cancer, tumor recurrence, prognosis, NFκB Received: September 01, 2015      Accepted: February 06, 2016      Published: March 02, 2016 ABSTRACT Conventional high-recurrence risk factors are not sufficient to predict post-operative risk of tumor recurrence or sensitivity to 5-fluorouracil (5-FU)-based chemotherapy for stage II colon cancer. DDA1, an evolutionarily conserved gene located at 19p13.11, may be involved in the activation of nuclear factor kappaB (NFκB). This study aimed to investigate whether DDA1 contributes to tumorigenesis and progression of stage II colon cancer via activation of the NFκB pathway. We found that positive expression of DDA1 alone or in combination with p65 nuclear translocation correlated with increased risk of tumor recurrence in patients with stage IIB–IIC colon cancer. DDA1 overexpression in colon cancer lines promoted cell proliferation, facilitated cell cycle progression, inhibited 5-FU-induced apoptosis, enhanced invasion, and induced the epithelial-mesenchymal transition. Suppression of DDA1 inhibited tumor progression, and reduced tumor growth in vivo . We also demonstrated that DDA1-mediated tumor progression is associated with the activation of the NFκB/COP9 signalosome 2(CSN2)/glycogen synthase kinase3β (GSK3β) pathway. These results indicate that DDA1 promotes colon cancer progression through activation of NFκB/CSN2/GSK3β signaling. DDA1, together with NFκB activation status, may serve as a sensitive biomarker for tumor recurrence risk and prognosis in patients with stage IIB–IIC colon cancers." @default.
• W2335863544 created "2016-06-24" @default.
• W2335863544 creator A5002075826 @default.
• W2335863544 creator A5009343195 @default.
• W2335863544 creator A5012313119 @default.
• W2335863544 creator A5014919039 @default.
• W2335863544 creator A5026049732 @default.
• W2335863544 creator A5029241959 @default.
• W2335863544 creator A5044470622 @default.
• W2335863544 creator A5046388497 @default.
• W2335863544 creator A5054188541 @default.
• W2335863544 creator A5055316643 @default.
• W2335863544 creator A5058010200 @default.
• W2335863544 creator A5061028143 @default.
• W2335863544 creator A5064662894 @default.
• W2335863544 creator A5064785596 @default.
• W2335863544 creator A5068528880 @default.
• W2335863544 creator A5070212853 @default.
• W2335863544 creator A5070646762 @default.
• W2335863544 creator A5070685306 @default.
• W2335863544 creator A5074665635 @default.
• W2335863544 creator A5081645087 @default.
• W2335863544 creator A5082386342 @default.
• W2335863544 creator A5082761011 @default.
• W2335863544 creator A5087863203 @default.
• W2335863544 date "2016-03-02" @default.
• W2335863544 modified "2023-10-12" @default.
• W2335863544 title "DDA1 promotes stage IIB-IIC colon cancer progression by activating NFκB/CSN2/GSK-3β signaling" @default.
• W2335863544 cites W125290639 @default.
• W2335863544 cites W1541556706 @default.
• W2335863544 cites W1726607518 @default.
• W2335863544 cites W1963501822 @default.
• W2335863544 cites W1964081206 @default.
• W2335863544 cites W1965110865 @default.
• W2335863544 cites W1976067359 @default.
• W2335863544 cites W1976859420 @default.
• W2335863544 cites W1983074899 @default.
• W2335863544 cites W1984264526 @default.
• W2335863544 cites W1985585046 @default.
• W2335863544 cites W2007420407 @default.
• W2335863544 cites W2008802992 @default.
• W2335863544 cites W2010927151 @default.
• W2335863544 cites W2013101563 @default.
• W2335863544 cites W2014058353 @default.
• W2335863544 cites W2018531445 @default.
• W2335863544 cites W2021344005 @default.
• W2335863544 cites W2035248532 @default.
• W2335863544 cites W2068784898 @default.
• W2335863544 cites W2087367170 @default.
• W2335863544 cites W2088106349 @default.
• W2335863544 cites W2109467988 @default.
• W2335863544 cites W2110107948 @default.
• W2335863544 cites W2117618256 @default.
• W2335863544 cites W2117692326 @default.
• W2335863544 cites W2121700962 @default.
• W2335863544 cites W2122483745 @default.
• W2335863544 cites W2126598648 @default.
• W2335863544 cites W2126780443 @default.
• W2335863544 cites W2127951115 @default.
• W2335863544 cites W2133950973 @default.
• W2335863544 cites W2137652355 @default.
• W2335863544 cites W2145052109 @default.
• W2335863544 cites W2146294374 @default.
• W2335863544 cites W2152032358 @default.
• W2335863544 cites W2155838330 @default.
• W2335863544 cites W2158524682 @default.
• W2335863544 cites W2162596488 @default.
• W2335863544 cites W2163549507 @default.
• W2335863544 cites W2169961966 @default.
• W2335863544 cites W2170111517 @default.
• W2335863544 cites W2219978888 @default.
• W2335863544 cites W2352440053 @default.
• W2335863544 cites W2402172082 @default.
• W2335863544 doi "https://doi.org/10.18632/oncotarget.7847" @default.
• W2335863544 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4991419" @default.
• W2335863544 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26942699" @default.
• W2335863544 hasPublicationYear "2016" @default.
• W2335863544 type Work @default.
• W2335863544 sameAs 2335863544 @default.
• W2335863544 citedByCount "6" @default.
• W2335863544 countsByYear W23358635442016 @default.
• W2335863544 countsByYear W23358635442018 @default.
• W2335863544 countsByYear W23358635442019 @default.
• W2335863544 countsByYear W23358635442021 @default.
• W2335863544 countsByYear W23358635442023 @default.
• W2335863544 crossrefType "journal-article" @default.
• W2335863544 hasAuthorship W2335863544A5002075826 @default.
• W2335863544 hasAuthorship W2335863544A5009343195 @default.
• W2335863544 hasAuthorship W2335863544A5012313119 @default.
• W2335863544 hasAuthorship W2335863544A5014919039 @default.
• W2335863544 hasAuthorship W2335863544A5026049732 @default.
• W2335863544 hasAuthorship W2335863544A5029241959 @default.
• W2335863544 hasAuthorship W2335863544A5044470622 @default.
• W2335863544 hasAuthorship W2335863544A5046388497 @default.
• W2335863544 hasAuthorship W2335863544A5054188541 @default.
• W2335863544 hasAuthorship W2335863544A5055316643 @default.
• W2335863544 hasAuthorship W2335863544A5058010200 @default.
• W2335863544 hasAuthorship W2335863544A5061028143 @default.

• next